AE Management for Combination Regimens in Advanced RCC

The key opinion leaders engage in discussion on dose reduction and treatment duration rates in the context of the CLEAR study, which investigated lenvatinib plus pembrolizumab in advanced renal cell carcinoma (RCC), addressing important aspects such as optimal starting doses, the potential for reverting to higher doses, and the implications of these strategies on overall treatment efficacy and patient outcomes.

EP: 1.Evolving Treatment Standards in Non-Clear Cell RCC

EP: 2.Extended Follow Up of KEYNOTE-B61

EP: 3.Ongoing Clinical Trials in the front-line setting of advanced non-clear cell RCC

EP: 4.STELLAR 304: Zanzalintinib plus nivolumab in non-clear cell RCC

EP: 5.Case Presentation: 61-year-old male Renal Cell Carcinoma

EP: 6.Use of Combination Regimens in Frontline RCC

EP: 7.Treatment Decision Making in first-line combinations for advanced RCC

EP: 8.AE Management for Combination Regimens in Advanced RCC

Now Viewing

EP: 9.AE Management for Combination Regimens in Advanced RCC

EP: 10.Optimizing Treatment in Advanced RCC

EP: 11.Dr Albiges Discusses a Non-Clear Cell RCC Patient Profile

EP: 12.Updates in the Treatment Approach for Non-clear cell RCC

EP: 13.Dr Albiges Reviews Long term follow up data from KEYNOTE-B61

1. Please comment on dose reduction and treatment duration rates in the CLEAR study and real-world experience. (Motzer JCO 2024).
   1. What are the typical starting doses for lenvatinib and pembrolizumab in your practice?
   2. What is your approach to dose reductions and reverting to higher doses in your practice?
2. What are some commonly observed adverse events with IO-TKI regimens?
   1. What strategies do you implement to mitigate and monitor for common side effects?
   2. What interventions help promote early AE detection and proactive mitigation?

Related Videos